Nanobiosensors in Healthcare Market Size was valued at USD 0.39 Billion in 2023. The Global Nanobiosensors in Healthcare industry is projected to grow from USD 0.43 Billion in 2024 to USD 0.98 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.11% during the forecast period (2024 - 2032).
Nanotechnology in the biosensor is known as nanobiosensor; biosensors are analytical devices used for detection of chemical and biological substances in the human body. Nanobiosensors are the sensors that are made up of nanomaterials and have dimensions between 1 to 100 nanometers. Nanobiosensors are becoming popular in developed countries. The rising prevalence of diabetes in emerging economies, demand for advanced monitoring systems, and raising awareness about advance nanobiosensors are expected to drive the growth of the market.
According to the International Diabetes Federation (IDF), it is estimated that the number of diabetic patients in the Middle East and North Africa (MENA) region will grow by 96% from the year 2013 to 2035, i.e., from 34.6 million to 67.9 million. Moreover, rising R&D spending and collaborative strategies adopted by the top players, such as new product launches and collaborations for product development are contributing to the growth of the market.
The rising cost of nanobiosensors and unfavorable reimbursement policies may hamper the growth of the market during the assessment period.
Nanobiosensors are analytical tools that detect chemical and biological compounds in the human body. Nanotechnology is employed in biosensors, and this technology is known as nano biosensors. It is anticipated that advancing nanotechnology techniques and obtaining knowledge of nanoscale phenomena will be essential for enhancing the functionality of already-developed nanosensors and assisting researchers in creating new nanosensors based on novel mechanisms.
Real-time reaction signals produced by nano biosensors are simple to gather and examine. The nano biosensors use a variety of nanomaterials, comprising nanotubes, nanoparticles, nanocrystals, nanowires, and nanocomposites. An ecosystem's availability of natural assets, such as healthy soil and readily available ground water, can be assessed using nano biosensors.
Farmers can monitor and control the regional soil conditions using this lightweight, portable equipment for the agricultural industry. Nano biosensors have been used to analyze pH, water content, soil fertility, mineral concentrations, and pest identification before the onset of illnesses. Nanobiosensors are nanomaterial-based sensors with sizes ranging from 1 to 100 nanometers.
In industrialized nations, nano biosensors are becoming more and more common. The market is anticipated to increase due to factors such as the increasing incidence of diabetes in developing nations, the demand for sophisticated monitoring systems, and growing public awareness of cutting-edge nano biosensors. The caliber of research businesses may access, the availability of funding sources, and supporting policy frameworks, notably in the healthcare and food sectors, are major elements influencing the market under study.
Additionally, the infestation of food with bacteria during its preservation and processing is another problem that is raising concerns across the globe. It is vitally important to develop new sustainable approaches and procedures to boost the effectiveness of natural resources, plant hormones, various illnesses, herbicides, fertilizers, and metal ions to produce agricultural and food items. Nano biosensors are gaining popularity as potential tools for agricultural and food production. Compared to conventional chemical and biological techniques, they offer considerable gains in selection, speed, and sensitivity. The determination of bacteria, toxins, contaminants, and food freshness can be done with nano biosensors.
The nanobiosensors in healthcare market has been segmented on the basis of type, application, end user, and region.
On the basis of type, the market has been classified as optical nanobiosensors, electrochemical nanobiosensors, acoustic nanobiosensors, and others. Based on the application, the market has been segmented into diabetes, immunoassay, cancer, pathogenic bacteria, and others.
The market, by end user, has been classified as hospitals and clinics, diagnostic centers, point of care, and others. The electrochemical nanobiosensors segment is expected to hold the largest market share of the nanobiosensors in healthcare market owing to its high sensitivity and real-time detection features. However, based on end user point of care testing segment holds the largest market share due to low complex infrastructure and training.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nanobiosensors in the healthcare market in the Americas has further been segmented into North America and South America, with the North America market further divided into the US and Canada.
The European nanobiosensors in the healthcare market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The nanobiosensors in healthcare market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The nanobiosensors in healthcare market in the Middle East & Africa has been segmented into the Middle East and Africa.
Some of the key players in the nanobiosensors in healthcare market are:
Researchers at the MIT Koch Institute for Integrative Cancer Research created enzyme-targeting nanoscale tools to map enzyme activity to areas within a tumor, extract relevant cell populations for study, and track cancer growth and therapy response in real-time. Their findings were recently published in Nature Communications. Researchers could use the nanosensors to gain insight into the molecular biology of cancer and create new tools for identifying, tracking, and treating the disease, while clinicians could use them to tailor treatments to a patient's specific cancer and monitor cancer progression and therapy response. The goal of the current study was to see whether this technology might be used to follow the progression of cancer correctly and sensitively over time as well as how it responds to various therapies. To target the overexpressed proteases in a mouse non-small cell lung cancer model, the scientists developed a panel of 14 nanoparticles.
The Americas are likely to dominate the nanobiosensors in healthcare market owing to the rising prevalence of chronic disorders, initiative by government and regulatory authorities, and demands for advanced technology. According to the report published by the US Department of Health & Human Services, in 2017, around 11.5% of the adult population in the US are diagnosed with heart disease, i.e., 28.2 million.
The European market is expected to be the second largest nanobiosensors in healthcare market. The market growth in this region can be attributed to the government focus to control chronic disease, well-established healthcare infrastructure, and the rising population suffering from cardiovascular disorders. Moreover, government funding and support to the healthcare sector are also expected to boost the growth of the nanobiosensors in healthcare market during the forecast period. According to the European Heart Network, cardiovascular disorders are responsible for 3.9 million deaths in the European Union, which are 45% of the total deaths.
Asia-Pacific is expected to be the fastest-growing nanobiosensors in healthcare market during the forecast period owing to rising diabetes, increasing disposable income, and government initiatives for the development of the healthcare sector. According to the International Diabetes Federation, in 2017, more than 84 million people in South-East Asia were affected by diabetes, and this number is expected to reach 156 million by 2045. Moreover, the government of these countries is open to adopting new technology and the best treatment option from a developed country. According to the International Agency for Research on Cancer, in 2018, India has a prevalence of 173.5 cancer patients per 100,000 population. Moreover, in China, the prevalence rate of cancer was 377.6 patients per 100,000 population in 2018
The market in the Middle East & Africa is expected to hold the smallest share of the global nanobiosensors market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities
Intended Audience
| Report Attribute/Metric | Details |
| Â Â Market Size | Â 0.98 Billion |
| Â Â CAGR | Â Â 11.11% (2024-2032) |
| Â Â Base Year | Â Â 2023 |
| Â Â Forecast Period | Â Â 2024-2032 |
| Â Â Historical Data | Â Â 2020 |
| Â Â Forecast Units | Â Â Value (USD Billion) |
| Â Â Report Coverage | Â Â Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered | Â Â Type, Application, End user |
| Â Â Geographies Covered | Â Â North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Â Â Key Vendors | Â Â Abbott Point of Care, Inc., F. Hoffman-LA Roche Ltd., Medtronic Inc., Nano-Proprietary, Inc., Lifescan, Inc., Illuminex Corporation, Lifesensors, Inc., ACON Laboratories, Inc., Pharmaco-Kinesis Corporation, Bayer Healthcare AG, Bio-Rad Laboratories, Inc., Biosensors International Pte. Ltd., Sysmex Corporation. |
| Â Â Key Market Opportunities | Â Â New product launches and R&D Amongst major key Players |
|   Key Market Drivers | · Rising prevalence of diabetes in emerging economies Demand for advanced monitoring systems · Raising awareness about advance nanobiosensors |
Nanobiosensors in Healthcare Market Highlights:
Frequently Asked Questions (FAQ) :
Nanobiosensors in healthcare market is projected to grow at a 11.11% CAGR between 2024-2032.
The Americas is expected to dominate the nanobiosensors in healthcare market.
Increasing prevalence of diabetes and awareness about advance nanobiosensors are the key factors driving the nanobiosensors in healthcare market.
Unfavorable reimbursement policies and rising cost may limit the nanobiosensors in healthcare market.
The electrochemical nanobiosensors segment will dominate the nanobiosensors in healthcare market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
